Alpha Teknova, Inc.
Alpha Teknova, Inc. (Nasdaq: TKNO) produces critical reagents used in the discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. Its products include pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and… From the company’s description.
Over the twelve months to Sep 30, 2026, Alpha Teknova, Inc. reported revenue of $45.95M, up 15.4% from a year earlier, and a net loss of $15.97M. Its operating margin was −32.7%, and operations used $5.57M in cash. In fiscal 2025, it reported revenue of $40.52M, up 7.4% from fiscal 2024, and a net loss of $17.26M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alpha Teknova, Inc. does
In the company’s own words
Alpha Teknova, Inc. (Nasdaq: TKNO) produces critical reagents used in the discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. Its products include pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. Customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics businesses, and academic and government research institutions. Teknova’s two product categories are Lab Essentials, which provides research-use products and accounted for 76.6% of 2025 revenue, and Clinical Solutions, which provides custom and GMP-grade products for diagnostic and therapeutic development and production and accounted for 18.9%. Customers use its formulations in areas including cell and gene therapies, mRNA vaccines, genomics, and molecular diagnostics. The company serves more than 3,000 customers and had 158 employees as of December 31, 2025. Its products are manufactured at facilities in Hollister, California.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- HOLLISTER, CA
- Fiscal year end
- December
- CIK
- 1850902
- SIC
- 2835
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alpha Teknova, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alpha Teknova, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alpha Teknova, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alpha Teknova, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alpha Teknova, Inc.'s last four quarterly filings that the numbers alone won't show?”